bluebird bio (NASDAQ:BLUE)‘s stock had its “overweight” rating restated by stock analysts at Barclays in a research note issued to investors on Wednesday. They currently have a $209.00 price objective on the biotechnology company’s stock, up from their previous price objective of $162.00. Barclays’ price target would suggest a potential upside of 13.37% from the company’s current price.

Several other brokerages have also recently weighed in on BLUE. Wells Fargo & Company reissued an “outperform” rating and set a $242.00 price objective (up from $190.00) on shares of bluebird bio in a research note on Tuesday. SunTrust Banks boosted their price objective on bluebird bio to $223.00 and gave the stock a “buy” rating in a research note on Tuesday. Cantor Fitzgerald set a $113.00 price objective on bluebird bio and gave the stock an “underweight” rating in a research note on Monday. Jefferies Group raised bluebird bio from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $130.00 to $211.00 in a research note on Monday. Finally, BMO Capital Markets set a $215.00 price objective on bluebird bio and gave the stock a “buy” rating in a research note on Monday. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $157.45.

bluebird bio (NASDAQ BLUE) traded down $0.55 during trading hours on Wednesday, hitting $184.35. The company had a trading volume of 1,719,500 shares, compared to its average volume of 866,462. bluebird bio has a 12 month low of $60.95 and a 12 month high of $222.03.

bluebird bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) EPS for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.05). The firm had revenue of $7.71 million during the quarter, compared to analysts’ expectations of $8.47 million. bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. bluebird bio’s quarterly revenue was up 397.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($2.07) earnings per share. analysts anticipate that bluebird bio will post -6.72 EPS for the current fiscal year.

In related news, Director Mark Vachon sold 7,000 shares of the stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $216.64, for a total value of $1,516,480.00. Following the transaction, the director now owns 8,000 shares of the company’s stock, valued at $1,733,120. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Jeffrey T. Walsh sold 9,900 shares of the stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $216.54, for a total value of $2,143,746.00. Following the completion of the transaction, the insider now directly owns 37,205 shares in the company, valued at approximately $8,056,370.70. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 97,582 shares of company stock worth $15,597,932. Insiders own 3.90% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Ladenburg Thalmann Financial Services Inc. grew its stake in bluebird bio by 454.2% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock worth $136,000 after purchasing an additional 813 shares in the last quarter. QS Investors LLC grew its stake in bluebird bio by 70.7% in the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 500 shares in the last quarter. Biondo Investment Advisors LLC bought a new position in bluebird bio in the third quarter worth approximately $203,000. World Asset Management Inc bought a new position in bluebird bio in the third quarter worth approximately $230,000. Finally, Bank of Montreal Can grew its stake in bluebird bio by 118.9% in the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 911 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: “bluebird bio (BLUE) Rating Reiterated by Barclays” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/12/15/bluebird-bio-blue-rating-reiterated-by-barclays.html.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Stock Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related stocks with our FREE daily email newsletter.